A. Chaitanya, M. Ashok Kumar, A. Gokul Krishna, P. Shanmugasundaram.
A. Chaitanya*, M. Ashok Kumar, A. Gokul Krishna, P. Shanmugasundaram.
Department of Pharmacy Practice, School of Pharmaceutical Sciences, VISTAS, Vels University,
Chennai-600117, Tamil Nadu, India
Volume - 9,
Issue - 11,
Year - 2016
Aim and objective: To assess the efficacy of Etanercept and also to evaluate the safety profile of Etanercept in patients with Rheumatoid arthritis. The main objectives of the study are to evaluate the drug safety and efficacy among the Rheumatoid arthritis patients. And to monitor the ADRs observed in Rheumatoid arthritis patients with Etanercept. Materials and Methods: Study was carried out in a 300 bedded tertiary care hospital. The department selected for the study was orthopaedics. This method involves prospective observational analysis of Efficacy and safety of Etanercept in patients with Rheumatoid arthritis. The study was carried out by the collection and documentation of general information of the patient including personal history, past medical history, past medication history, lab investigations and treatment pain will be analysed by using visual analog scale(vas). ADR’s were assessed by using Naranjo adverse drug reaction probability scale. The whole procedure was carried out in Rheumatoid arthritis patients who received Etanercept without any alteration in therapy. Result and Discussion: This study on sample size of 35 was carried out to assess the short term safety and efficacy of Etanercept. Moreland et al compared placebo, ETN 10 mg twice weekly (ETN20), and ETN 25 mg twice weekly (ETN50) in patients with long-standing RA and an inadequate response to DMARDs. Although both treatment arms were significantly better than placebo, as measured by American College of Rheumatology.
The study conducted by Elizabeth Mary Curtis et al., shows that Etanercept is a safe and well-tolerated treatment for RA, And another study conducted by Boulos Haraoui et al, study shows that Etanercept is both safe and effective to use in RA. Etanercept has been shown not only to reduce disease activity but also to limit progression of joint damage in early and late disease which are similar to our study. Conclusion: This study concludes incidence of rate of patients in the age group of 50 – 59 years were mostly affected by Rheumatiod arthritis compared to other age groups. The male patients were found to be affected more with rheumatoid arthritis than female patients. The study made use of 25mg Eternacept for the above obtained results. This could also be carried out using 50mg Eternacept and evaluated on the same. There was a decrease in pain VAS scale confirming the efficacy and safety of Etanercept. In the future, this study could be further extended to a combination therapy over longer duration of time for better results.
Cite this article:
A. Chaitanya, M. Ashok Kumar, A. Gokul Krishna, P. Shanmugasundaram. A Study on Efficacy and Safety of Etanercept in Patients with Rheumatoid Arthritis. Research J. Pharm. and Tech 2016; 9(11): 1933-1936. doi: 10.5958/0974-360X.2016.00396.6
A. Chaitanya, M. Ashok Kumar, A. Gokul Krishna, P. Shanmugasundaram. A Study on Efficacy and Safety of Etanercept in Patients with Rheumatoid Arthritis. Research J. Pharm. and Tech 2016; 9(11): 1933-1936. doi: 10.5958/0974-360X.2016.00396.6 Available on: https://rjptonline.org/AbstractView.aspx?PID=2016-9-11-25